|
(PQA2) Impact of obesity on endogenous mutational hotspots
|
1R21CA185508-01
|
$201,623
|
$201,623
|
VASQUEZ, KAREN
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
(PQD1) Treatment-emergent resistance to NEDD8-activating enzyme inhibition
|
3R01CA180150-02S1
|
$108,952
|
$108,952
|
PETROSKI, MATTHEW
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
(PQD1) Treatment-emergent resistance to NEDD8-activating enzyme inhibition
|
5R01CA180150-02
|
$541,578
|
$541,578
|
PETROSKI, MATTHEW
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
|
5R21CA180097-02
|
$192,409
|
$192,409
|
DITTMER, DIRK
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
1R01CA185372-01
|
$329,519
|
$329,519
|
RICHARDS, KRISTY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
(PQD5)Biomaterials-based Adaptive Tumor Microenvironments for In Vitro Drug Scree
|
1R21CA185236-01
|
$179,619
|
$179,619
|
SINGH, ANKUR
|
CORNELL UNIVERSITY
|
|
00000000; D.GUY; SEVERABLE OPERATIONS FOR NCI-FREDERICK
|
261200800001E
|
$296,673,020
|
$603,009
|
Heimbrook, David
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
A bifunctional nanomedicine for both specific imaging and targeting therapy of an
|
5R01CA151955-05
|
$300,665
|
$300,665
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 - 02060
|
$286,453
|
$57,291
|
Rothman, Nathaniel
|
DCEG (NCI)
|
|
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
|
5R01CA156674-04
|
$305,437
|
$305,437
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A Modifier of Plasmacytoma Susceptibility Maps to Mouse Chr 1
|
ZIA BC 011064
|
$109,375
|
$21,875
|
Mock, Beverly
|
CCR (NCI)
|
|
A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)
|
ZIA CP010136 - 10512
|
$1,457,188
|
$1,457,188
|
Lan, Qing
|
DCEG (NCI)
|
|
A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
|
5U54CA155496-04
|
$1,660,228
|
$448,262
|
COLDITZ, GRAHAM
|
WASHINGTON UNIVERSITY
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
2R44CA159843-02
|
$748,921
|
$748,921
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
A new technology to isolate RNP complexes of a polycistronic miRNA oncogene
|
5R21CA175560-02
|
$194,176
|
$194,176
|
HE, LIN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose
|
1R01CA190696-01
|
$316,610
|
$316,610
|
SCHATZ, JONATHAN
|
UNIVERSITY OF ARIZONA
|
|
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides
|
1R03CA184127-01
|
$84,750
|
$84,750
|
DIEFENBACH, CATHERINE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-02
|
$326,066
|
$163,033
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-26
|
$242,092
|
$79,890
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
1R44CA183316-01
|
$190,601
|
$190,601
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-04
|
$577,153
|
$577,153
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$225,712
|
$22,571
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-38S1
|
$74,997
|
$3,750
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-38
|
$7,449,701
|
$372,485
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$381,093
|
$190,546
|
Aplan, Peter
|
CCR (NCI)
|
|
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu
|
1U54CA190152-01
|
$697,934
|
$321,050
|
GOPAL, SATISH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Adult Leukemia Research Center
|
5P01CA018029-39
|
$4,098,686
|
$368,882
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-08S1
|
$6,300,000
|
$1,260,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
5U01CA121947-08
|
$1,900,000
|
$380,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
1U10CA180821-01
|
$10,540,919
|
$527,046
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S1
|
$228,063
|
$11,403
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S2
|
$264,661
|
$13,233
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S3
|
$16,838
|
$842
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$209,461
|
$69,122
|
Kochenderfer, James
|
CCR (NCI)
|
|
Allotransplant for DOCK8 deficiency
|
ZIA BC 011374
|
$274,903
|
$137,451
|
Hickstein, Dennis
|
CCR (NCI)
|
|
Alpha Radioimmunotherapy for Lymphoma Treatment
|
5R01CA172582-02
|
$640,365
|
$640,365
|
SANDMAIER, BRENDA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Alternative Cleavage and Polyadenylation Events as Biomarkers
|
5R03CA167752-02
|
$73,720
|
$73,720
|
WAGNER, ERIC
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
Alternative End-Joining in DNA Repair and Chromosomal Translocations
|
1F30CA189740-01
|
$34,970
|
$34,970
|
KUMAR, VIPUL
|
HARVARD MEDICAL SCHOOL
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
2R42CA183708-03A1
|
$509,024
|
$509,024
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,360,387
|
$136,039
|
Oberholtzer, J.
|
CCR (NCI)
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$1,184,484
|
$236,897
|
DuBois, Wendy
|
CCR (NCI)
|
|
Annual International Primary CNS Lymphoma Collaborative Group Meeting
|
2R13CA124293-08
|
$5,000
|
$5,000
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Antagonizing oncogenic microRNAs for the elucidation and treatment of lymphoma
|
5F32CA174247-02
|
$53,282
|
$53,282
|
CHENG, CHRISTOPHER
|
YALE UNIVERSITY
|
|
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
|
5R21CA178344-02
|
$155,521
|
$116,641
|
ARMENIAN, SARO
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Antibody-CpG conjugates for the treatment of B cell lymphoma
|
5R01CA149254-05
|
$300,665
|
$300,665
|
TIMMERMAN, JOHN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Antibody-interferon fusion proteins for treatment of B-cell malignancies
|
5R01CA162964-04
|
$309,964
|
$309,964
|
MORRISON, SHERIE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Anticancer drug-induced BH3-only protein.Bak interactions
|
5R01CA166741-03
|
$311,815
|
$311,815
|
KAUFMANN, SCOTT
|
MAYO CLINIC ROCHESTER
|
|
Apoptosis Mechanisms and Human Cancer
|
5R01CA082197-15
|
$241,569
|
$169,098
|
WANG, HONG-GANG
|
PENNSYLVANIA STATE UNIVERSITY
|
|
Approaches to discover and quantify apoptotic biomarkers for cancer treatment
|
5R01CA154802-04
|
$310,970
|
$155,485
|
WELLS, JAMES
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S2
|
$3,835,199
|
$306,816
|
CRESS, ANNE
|
UNIVERSITY OF ARIZONA
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $118,049,565
|